About HTL Biotechnology
HTL Biotechnology is a Healthcare company based in Javene (France) founded in 1992, and was acquired by Montagu in November 2021. Biopolymers based on hyaluronic acid are developed for therapeutic uses. Its chief executive, as recorded, is Yvon Bastard. Its website htlbiotech.com draws about 10 thousand monthly visits. HTL Biotechnology offers products and services including Hyaluronic Acid, Polynucleotides, Sodium DNA, Recombinant Human Collagen III, and Heparosan. Its focus areas include Life Sciences, Regenerative Medicine, Biomaterials and Diversified.
Company details
HTL Biotechnology was established in 1992 in Javene, France, within the biotechnology sector. Biopolymers, particularly hyaluronic acid, are developed for medical applications. These include use as dermal fillers, protection of eye tissue during surgical procedures, treatments for osteoarthritis, and surface coatings for medical devices. Operations focus on advancing biopolymer technologies for therapeutic and device-related purposes.
- Headquarters Javene, France
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website htlbiotech.com
- Social LinkedIn Instagram YouTube
- Acquired by Montagu (Nov 2021)
- InvestorsPartners Group
& 2 more
- Acquired by
Products & Services of HTL Biotechnology
HTL Biotechnology offers a comprehensive portfolio of products and services, including Hyaluronic Acid, Polynucleotides, Sodium DNA, Recombinant Human Collagen III, and Heparosan.
Premium pharma-grade for medical and cosmetic treatments.
Premium grade for dermatology and beauty applications.
Cosmetic-grade for skincare and related uses.
New recombinant collagen for unique medical properties.
Opportunities in medical applications beyond hyaluronic acid.
Ultra-low molecular weight for advanced treatments.
Investors in HTL Biotechnology
HTL Biotechnology has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Partners Group, Bridgepoint Capital and Montagu Private Equity.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity funds are managed across multiple sectors globally. | 1996 | partnersgroup.com | Baar, Switzerland | |
Montagu Private Equity is engaged in mid-market business investments. | montagu.com | Frankfurt, Germany | ||
Middle-market businesses up to €1 billion are acquired pan-Europe. | 1984 | bridgepoint.eu | Frankfurt, Germany |
Investor details for HTL Biotechnology
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of HTL Biotechnology
20 people are tracked at HTL Biotechnology (8 in leadership, 12 in team).
| Name | Role | Group |
|---|---|---|
Yvon Bastard | CEO | Leadership |
François Fournier | CEO | Leadership |
Cyril Picault | Chief Operating Officer | Leadership |
Emmanuel Lefèvre | Chief HR Officer | Leadership |
Laurène Brodiez | Chief Commercial Officer | Leadership |
Nicolas Préfol | Chief Financial Officer | Leadership |
Anne - Laure Gaudry | Head Of Innovation And R&d | Leadership |
Francis B Maddalo | Site Head/ COO | Leadership |
Natalia Iyke | Senior Research Scientist | Team |
Léa Messager | R&d Chemistry Lab Manager | Team |
Alizé Jaouen | Responsable Achats | Team |
Anne Joncour | Contrôleur De Gestion | Team |
Chloë Ferris | Responsable Comptable | Team |
Florian Vacheresse | Responsable Administratif Et Financier | Team |
Nolwenn Lorin | Responsable De Programme | Team |
Pierre-André Letard | Acheteur | Team |
Inès Gaddoumi | Senior Manager Business Development | Team |
Peter Bae | Sales Agency For Korean Market | Team |
Clément Georgoux | Product Manager | Team |
Nicolas Ory | Responsable Fabrication | Team |
Complete people profiles for HTL Biotechnology
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of HTL Biotechnology
3 dated milestones of HTL Biotechnology across 29 years, from founding to its latest funding, stage changes and deals.
- Founded HTL Biotechnology is founded.
- Exit Acquired by Bridgepoint Capital.
- Exit Acquired by Montagu.
Web traffic of HTL Biotechnology
The website of HTL Biotechnology (htlbiotech.com) receives about 10.1K visits a month.
- Monthly visits10.1K
▼ 11.8% vs previous month
Websites whose visitors overlap most with HTL Biotechnology. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
htlinternational.co.kr | htlinternational.co.kr | 100% | #9,742,496 | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Htl Biotechnology
Complete news archive for HTL Biotechnology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about HTL Biotechnology
HTL Biotechnology was founded in 1992.
HTL Biotechnology is headquartered in Javene, France. It is registered at Javene, Ille-et-vilaine, France.
Yvon Bastard is the CEO of HTL Biotechnology, as recorded in our data.
HTL Biotechnology was established in 1992 in Javene, France, within the biotechnology sector. Biopolymers, particularly hyaluronic acid, are developed for medical applications. These include use as dermal fillers, protection of eye tissue during surgical procedures, treatments for osteoarthritis, and surface coatings for medical devices. Operations focus on advancing biopolymer technologies for therapeutic and device-related purposes.
HTL Biotechnology offers Hyaluronic Acid, Polynucleotides, Sodium DNA, Recombinant Human Collagen III, and 2 more products and services.
HTL Biotechnology has 3 investors. Key investors include Partners Group, Bridgepoint Capital, and Montagu Private Equity.
Yes. HTL Biotechnology was acquired by Montagu in November 2021.